ReviewExpert review of anticancer therapy2015
New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy.
Review in Expert review of anticancer therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.Blood advances · 2026Trial
- A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).Blood advances · 2024Trial
- Article
- The need for a cancer exposome atlas: a scoping review.JNCI cancer spectrum · 2025Article
- MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1.Molecular and cellular biochemistry · 2025Article
- Development of a model to predict Ki-67 expression status in non-Hodgkin's lymphoma based on PET radiomics.Frontiers in oncology · 2025Article
- Changes in sex-specific incidence of lymphoid neoplasms across the lifespan.Haematologica · 2024Article
- Hysterectomy, oophorectomy and risk of non-Hodgkin's lymphoma.International journal of cancer · 2024Article
- Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.Cells · 2024Review
- A Rare Case of Low-Grade B-cell Non-Hodgkin's Lymphoma of the Lower Lip Mimicking a Mucocele.Cureus · 2024Article
- Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.Frontiers in immunology · 2024Article
- HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control study.Frontiers in genetics · 2024Article
- Article
- Different operationalizations of the 2018 WCRF/AICR cancer prevention recommendations and risk of cancer.British journal of cancer · 2023Article
- Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.EClinicalMedicine · 2023Article
- Incidence Trend of Follicular Lymphoma in Taiwan Compared to Japan and Korea, 2001-2019.Journal of clinical medicine · 2023Article
- Self-reported causes of cancer among 6881 survivors with 6 tumour types: results from the PROFILES registry.Journal of cancer survivorship : research and practice · 2023Article
- Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.American journal of hematology · 2022Observational
- Extra-Nodal Lymphomas of the Head and Neck and Oral Cavity: A Retrospective Study.Current oncology (Toronto, Ont.) · 2022Article
- Association of antibiotic-consumption patterns with the prevalence of hematological malignancies in European countries.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Non-Hodgkin lymphoma (NHL) comprises numerous biologically and clinically heterogeneous subtypes, with limited data examining the risk factors for these distinct disease entities. Many limitations exist when studying lymphoma epidemiology; therefore, until recently, little was known regarding the etiology of NHL subtypes. This review highlights the results of recent pooled analyses examining the risk factors for NHL subtypes. We outline the heterogeneity and commonality among the risk factors for NHL subtypes, with proposed subtype-specific as well as shared etiologic mechanisms. In addition, we describe how the study of lymphoma epidemiology may translate into prevention or therapeutic targeting as we continue to explore the complexities of lifestyle and genetic factors that impact lymphomagenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.